
Giannis Mountzios/X
Feb 18, 2025, 18:35
Giannis Mountzios: Biomarker-selected or biomarker-agnostic ADCs for oncogene-addicted NSCLC
Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared his recent article on X:
“Biomarker-selected or biomarker-agnostic ADCs for oncogene-addicted NSCLC
Just out in ESMO Cancer Treatment Reviews a comprehensive overview on current landscape, challenges and perspectives.
Grateful to work with a global amazing team, including Stephanie Saw, Lizza Hendriks, Jessica Menis, Tina Cascone, Oscar Arrieta, Jarushka Naidoo, Alfredo Addeo, Solange Peters and senior author Jordi Remon.”
Authors: Giannis Mountzios, et al.
Alfredo Addeo
cancer
ESMO Cancer Treatment Reviews
fight against cancer
genomic alterations
Giannis Mountzios
Global awareness
Global fight against cancer
Henry Dunant Hospital Center
Jarushka Naidoo
Jessica Menis
Jordi Remon
Lizza Hendriks
NSCLC
OncoDaily
Oncology
Oscar Arrieta
Solange Peters
Stephanie Saw
Tina Cascone
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 18, 2025, 19:27
Feb 18, 2025, 19:12
Feb 18, 2025, 19:03
Feb 18, 2025, 18:55
Feb 18, 2025, 18:13
Feb 18, 2025, 17:57
Feb 18, 2025, 17:36